Back to Report Store Home

Frontier Pharma: Type 2 Diabetes Mellitus – GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

  • Published: Dec-2016
  • Report Code: GBIHC417MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Type 2 Diabetes Mellitus, Global, Innovation Trends in Product Approvals Across the Pharmaceutical Market, 1987–2014 6

Figure 2: Type 2 Diabetes Mellitus, Global, Post-Marketing-Approval Sales Performance of First-in-Class and Non-First-in-Class Products Across Pharmaceutical Industry ($m), 2006–2013 8

Figure 3: Type 2 Diabetes Mellitus, Global, Marketed Products by Molecule Type, 2016 22

Figure 4: Type 2 Diabetes Mellitus, Global, Marketed Products by Molecular Target, 2016 23

Figure 5: Type 2 Diabetes Mellitus, Global, Pipeline Size by Therapy Area, 2016 25

Figure 6: Type 2 Diabetes Mellitus, Global, Pipeline by Stage of Development and Molecule Type, 2016 26

Figure 7: Type 2 Diabetes Mellitus, Global, Pipeline by Molecular Target and Stage of Development, 2016 27

Figure 8: Type 2 Diabetes Mellitus, Global, Pipeline Breakdown of XXX, 2016 28

Figure 9: Type 2 Diabetes Mellitus, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2016 29

Figure 10: Type 2 Diabetes Mellitus, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2016 31

Figure 11: Type 2 Diabetes Mellitus, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Stage of Development, 2016 32

Figure 12: Type 2 Diabetes Mellitus, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Molecular Target Class, 2016 32

Figure 13: Type 2 Diabetes Mellitus, Global, Ratio of First-in-Class Targets to First-in-Class Products by Stage of Development, 2016 33

Figure 14: Type 2 Diabetes Mellitus, Global, Ratio of First-in-Class Targets to First-in-Class Products by Molecular Target, 2016 33

Figure 15: Type 2 Diabetes Mellitus, Global, All Pipeline Products, 2016 (part 1) 34

Figure 16: Type 2 Diabetes Mellitus, Global, All Pipeline Products, 2016 (part 2) 35

Figure 17: Type 2 Diabetes Mellitus, Global, All Pipeline Products, 2016 (part 3) 36

Figure 18: Type 2 Diabetes Mellitus, Global, All Pipeline Products, 2016 (part 4) 37

Figure 19: Type 2 Diabetes Mellitus, Global, All Pipeline Products, 2016 (part 5) 38

Figure 20: Type 2 Diabetes Mellitus, Global, All Pipeline Products, 2016 (part 6) 39

Figure 21: Type 2 Diabetes Mellitus, Global, All Pipeline Products, 2016 (part 7) 40

Figure 22: Type 2 Diabetes Mellitus, Global, All Pipeline Products, 2016 (part 8) 41

Figure 23: Type 2 Diabetes Mellitus, Global, All Pipeline Products, 2016 (part 9) 42

Figure 24: Type 2 Diabetes Mellitus, Global, All Pipeline Products, 2016 (part 10) 43

Figure 25: Type 2 Diabetes Mellitus, Global, All Pipeline Products, 2016 (part 11) 44

Figure 26: Type 2 Diabetes Mellitus, Global, All Pipeline Products, 2016 (part 12) 45

Figure 27: Type 2 Diabetes Mellitus, Global, All Pipeline Products, 2016 (part 13) 46

Figure 28: Type 2 Diabetes Mellitus, Global, All Pipeline Products, 2016 (part 14) 47

Figure 29: Type 2 Diabetes Mellitus, Global, First-in-Class Molecular Target Analysis Matrix Part 1, 2016 50

Figure 30: Type 2 Diabetes Mellitus, Global, First-in-Class Molecular Target Analysis Matrix Part 2, 2016 51

Figure 31: Type 2 Diabetes Mellitus, Global, First-in-Class Molecular Target Analysis Matrix Part 3, 2016 52

Figure 32: Type 2 Diabetes Mellitus, Global, First-in-Class Molecular Target Analysis Matrix Part 4, 2016 53

Figure 33: Type 2 Diabetes Mellitus, Global, Industry-Wide Licensing Deals by Stage of Development, 2006–2016 68

Figure 34: Type 2 Diabetes Mellitus, Global, Industry-Wide Licensing Deals by Deal Value, Upfront Payment Value, Stage of Development and First-in-Class Status ($m), 2006–2014 69

Figure 35: Type 2 Diabetes Mellitus, Global, Licensing Deals by Region, Value and Year, 2006–2016 70

Figure 36: Type 2 Diabetes Mellitus, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2016 71

Figure 37: Type 2 Diabetes Mellitus, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type, 2006–2016 72

Figure 38: Type 2 Diabetes Mellitus, Global, Frequency and Aggregate Deal Value of Licensing Deals by Molecular Target, 2006–2016 72

Figure 39: Type 2 Diabetes Mellitus, Global, Co-development Deals by Region and Deal Value and Year, 2006–2016 75

Figure 40: Type 2 Diabetes Mellitus, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2016 76

Figure 41: Type 2 Diabetes Mellitus, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type, 2006–2016 76

Figure 42: Type 2 Diabetes Mellitus, Global, Frequency and Aggregate Deal Value of Co-development Deals by Molecular Target, 2006–2016 77

Figure 43: Type 2 Diabetes Mellitus, Global, Deal Involvement of First-in-Class Programs, 2016 (part 1) 80

Figure 44: Type 2 Diabetes Mellitus, Global, Deal Involvement of First-in-Class Programs, 2016 (part 2) 81

Figure 45: Type 2 Diabetes Mellitus, Global, Deal Involvement of First-in-Class Programs, 2016 (part 3) 82

Figure 46: Type 2 Diabetes Mellitus, Global, Deal Involvement of First-in-Class Programs, 2016 (part 4) 83

Figure 47: Type 2 Diabetes Mellitus, Global, Deal Involvement of First-in-Class Programs, 2016 (part 5) 84

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards